Every fortnight, every third week, seasonally: an unstudied practice
An absence of evidence is not evidence of harm. It is also not a licence.
The archive — 2025
Page 35 of 68 of this archive, newest first.
A supplier suspends shipping to Italy after 24 consecutive customs detentions
The route did not close because of a rule about peptides.
What a 32% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
Brazil caps tirzepatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
When to stop escalating and when to stop entirely
The ceiling varies severalfold between people, and nothing measurable at baseline predicts where it sits.
The certificate of analysis, line by line
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
What the new Portugal guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
SURPASS-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The Netherlands declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The one randomised trial that combined an incretin with supervised exercise
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
Gauge, pain and flow rate
The insulin injection-technique literature is large, well conducted and directly transferable on questions of depth and tissue. We say where it stops transferring.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What changed at SWB in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Argentina caps exenatide prescribing to 8 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The consolidator trading as Meridian Freight Partners closes after 17 years
A proper account of an operation that existed, and of what closing it cost.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Which results should be repeated before they are investigated
What the pivotal programmes measured and how often, which is a more defensible template than most published monitoring schedules.
The United Arab Emirates health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A shortage listing ends. 4 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What a 22% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
Two-thirds back: the extension nobody expected to be the headline
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Accuracy, precision and the tolerance nobody states
Parts per million sound impressive until they are converted into daltons at the molecular weight of the thing being measured.
The arithmetic of a step: what doubling a dose actually asks of you
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
The consolidator trading as Meridian Freight Partners closes after 8 years
A proper account of an operation that existed, and of what closing it cost.
The 7-day notice: how a compounding wind-down works in Australia
The document is four pages. Three of them are about dates.
QSC declines, for the 4th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A reference interval is not a target, and a result outside one is not a diagnosis
Almost every misreading of a laboratory panel is a misunderstanding of what a reference interval is and how much a result has to move before the movement means anything.
What the new Australia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.